Cel "Pharma73 SA is a Portuguese start-up dedicated to the development, production and commercialization of a new generationof High Functionality Excipients (HFEs). Excipients are inactive ingredients used together with active ingredients to formulatedrugs into finished dosage forms. Ranging from 15% to 95% of the total weight of a given drug, excipients are extremelyimportant in terms of procurement, logistics, quality control and final batch release. Pharma73’s technology is based on theproduction of natural polymers, such as the Chitin Glucan Complex HPE1, obtained from fermentation processes whoseunique properties enable their application in a multiplicity of pharmaceutical drugs for oral solid-dosage forms. Adding HPE1to the final drug formulation will result in better yields and operational savings for the manufacturing industry, thanks tosignificant functional - physical and chemical properties of the new excipient. Pharma73’s ambition is to introduce a new rawmaterial into the excipient markets, and bring the industry to a new level that better responds to efficiency and sustainabilityrequirements of the drug manufacturing process. Furthermore the innovation related to the adoption of HPE1 will preservethe EU’s competitive advantage over drug manufacturing procedures, creating more job opportunities, and the long-termviability of a European-based pharmaceutical industry. Therefore the commercialization of a novel class of excipients likeHPE1 aligns with the EU strategy “Europe 2020 – for a healthier EU”: 1) “Innovation can help make the healthcare sectormore sustainable” 2) “the healthcare sector has an important role to play in improving skills and creating jobs as it employs 1in 10 of the most qualified workers in the EU"".The SME instrument will allow Pharma 73 to complete their go-to-market strategy, by demonstrating HPE1 potential forspecific drug formulation uses." Dziedzina nauki engineering and technologymechanical engineeringmanufacturing engineeringmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsengineering and technologymaterials engineeringcompositesbiocompositessocial scienceseconomics and businessbusiness and managementbusiness modelsengineering and technologyindustrial biotechnologybioprocessing technologiesfermentation Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator PHARMA73 SA Wkład UE netto € 50 000,00 Adres HERDADE DO BURRAZEIRO RIO DE MOINHOS 7150 390 BORBA Portugalia Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Continente Alentejo Alentejo Central Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
